Related Experiment Video
Updated: Jul 16, 2026
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
Delayed diagnosis of infants with abnormal neonatal screens
R Listernick1, L Frisone, B L Silverman
1Department of Pediatrics, Children's Memorial Hospital, Chicago, IL 60614.
Insights
Many infants with screened conditions like 21-hydroxylase deficiency and hemoglobinopathies miss timely treatment. A system to directly contact parents of positive neonatal screening cases is recommended.
Area of Science:
- Neonatal screening
- Pediatric medicine
- Public health
Background:
- State neonatal screening programs identify infants with serious conditions.
- Timely medical intervention is crucial for managing these disorders.
Purpose of the Study:
- To identify infants diagnosed clinically with screened conditions who did not receive timely medical attention.
- To evaluate the impact of delayed diagnosis on infant health outcomes.
Main Methods:
- A descriptive case series was conducted over two years (1989-1991).
- Infants with clinically suspected and confirmed disease, and abnormal screening results were included.
- Data collected included age at diagnosis, morbidity, and follow-up.
Main Results:
- Ten infants were identified with 21-hydroxylase deficiency (3) or hemoglobinopathies (7).
- Clinical diagnosis was significantly delayed (mean 32 days for 21-hydroxylase deficiency, 215 days for sickle cell anemia).
- Six infants experienced potentially life-threatening complications due to delayed treatment.
Conclusions:
- A notable number of neonates with screened disorders do not receive timely treatment.
- Direct parental contact by screening programs for positive cases may improve timely care.
Objective:
To identify infants who were diagnosed clinically with a condition that previously had been detected by a state neonatal screening program, but who had failed to receive medical attention in a timely fashion.
Design:
A descriptive case series of infants over a 2-year period from 1989 to 1991.
Setting:
An academically affiliated tertiary care pediatric hospital, a major referral center for children with abnormal results on state neonatal screening tests.
Patients:
All patients who (1) had a diagnosis suspected clinically, (2) had confirmation of disease, and (3) were subsequently found to have had abnormal screening results.
Main Outcome Measures:
Age at clinical diagnosis, morbidity due to delay in diagnosis, and postnatal medical follow-up.
Results:
Ten children were identified, three with 21-hydroxylase deficiency and seven with a hemoglobinopathy. In each case, the screening program had clear documentation that the office of the physician of record had received prompt telephone communication of the abnormal result. The mean age at clinical diagnosis was 32 days for the children with 21-hydroxylase deficiency and 215 days for those with sickle cell anemia, substantially longer than is mandated by proper neonatal screening practice. Potentially life-threatening complications of the underlying disease were present in six children.
Conclusions:
A significant number of neonates who have metabolic disorders appropriately identified by a neonatal screening test may fail to receive timely treatment. Consideration should be given to implementing a system of directly contacting the parents of all presumptive positive cases by the state screening program.
